RxDoctor Payments Data

Richard Alling, MD

Internal Medicine · Canandaigua, NYNPI 1366443202

Payments from drug & device makers

$933in general payments, 2019–2025

Across 51 payments — averaging $18.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$358
  • Exact Sciences$131
  • Pfizer$120
  • Boehringer Ingelheim$93
  • Novo Nordisk$84
  • Takeda Pharmaceuticals U.S.A., Inc.$34
  • plus $113 from 6 others

What the payments were for

  • Food & beverage$933100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$933 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$15,830
Medicare patients
345
Services billed
493

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban120$93,452
TrulicityDulaglutide57$70,919
JardianceEmpagliflozin44$47,564
OzempicSemaglutide45$46,516
MounjaroTirzepatide34$42,825
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$33,762
ArexvyRsvpref3 Antigen/As01e/Pf116$33,487
Synjardy XrEmpagliflozin/Metformin Hcl22$15,771
XareltoRivaroxaban12$15,602
ShingrixVaricella-Zoster Ge/As01b/Pf70$14,348
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$10,315
Atorvastatin Calcium456$7,363
JanuviaSitagliptin Phosphate13$6,778
TradjentaLinagliptin11$6,341
Boostrix TdapDiphth,pertuss(Acell),tet Vac92$5,486

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$11$113,74591 claims
PfizerEliquis$120$93,452120 claims
GSKTrelegy Ellipta, Arexvy, Shingrix, Arnuity Ellipta$358$85,974240 claims
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta$93$69,67677 claims
Novo NordiskOzempic$84$46,51645 claims
MerckJanuvia$30$6,77813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Canandaigua

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →